Waffles_11的个人主页 - 老虎社区

Waffles_11

Waffles_11

暂无个人介绍

IP属地：未知

22关注

0粉丝

0主题

0勋章

2021-05-19

Awesome 👍🏼

抱歉，原内容已删除

2021-04-30

Wow nice 👍🏼

抱歉，原内容已删除

2021-06-08

👍🏼

FDA approves Biogen's Alzheimer's drug, the first new therapy for the disease in nearly two decades

2021-04-30

That's awesome!

抱歉，原内容已删除

2021-06-20

Good read

抱歉，原内容已删除

2021-06-19

Nice awesome

抱歉，原内容已删除

2021-05-10

Wow nice 👍🏼

Tesla Raises China Model 3 Prices, Citing Cost Fluctuations

2021-05-05

:(

EV stocks fell in morning trading Tuesday

2021-04-30

Wow awesome

25 Undervalued Stocks with Earnings Set to Beat Pre-Covid Levels in 2021

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3573681651019306","uuid":"3573681651019306","gmtCreate":1610688681412,"gmtModify":1620612165613,"name":"Waffles_11","pinyin":"waffles11waffles11","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/9d49a2f6994c90065ccb9ee9e61b94cd","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":22,"tweetSize":9,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":165625964,"gmtCreate":1624134788658,"gmtModify":1634010452276,"author":{"id":"3573681651019306","authorId":"3573681651019306","name":"Waffles_11","avatar":"https://static.tigerbbs.com/9d49a2f6994c90065ccb9ee9e61b94cd","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573681651019306","authorIdStr":"3573681651019306"},"themes":[],"htmlText":"Good read&nbsp;","listText":"Good read&nbsp;","text":"Good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/165625964","repostId":"1161408410","repostType":4,"isVote":1,"tweetType":1,"viewCount":205,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":162158121,"gmtCreate":1624048076563,"gmtModify":1634023616440,"author":{"id":"3573681651019306","authorId":"3573681651019306","name":"Waffles_11","avatar":"https://static.tigerbbs.com/9d49a2f6994c90065ccb9ee9e61b94cd","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573681651019306","authorIdStr":"3573681651019306"},"themes":[],"htmlText":"Nice awesome&nbsp;","listText":"Nice awesome&nbsp;","text":"Nice awesome","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/162158121","repostId":"2144775875","repostType":4,"isVote":1,"tweetType":1,"viewCount":246,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114783406,"gmtCreate":1623106245705,"gmtModify":1634037017242,"author":{"id":"3573681651019306","authorId":"3573681651019306","name":"Waffles_11","avatar":"https://static.tigerbbs.com/9d49a2f6994c90065ccb9ee9e61b94cd","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573681651019306","authorIdStr":"3573681651019306"},"themes":[],"htmlText":"👍🏼","listText":"👍🏼","text":"👍🏼","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/114783406","repostId":"1108033863","repostType":4,"repost":{"id":"1108033863","kind":"news","pubTimestamp":1623087360,"share":"https://www.laohu8.com/m/news/1108033863?lang=&edition=full","pubTime":"2021-06-08 01:36","market":"us","language":"en","title":"FDA approves Biogen's Alzheimer's drug, the first new therapy for the disease in nearly two decades","url":"https://stock-news.laohu8.com/highlight/detail?id=1108033863","media":"cnbc","summary":"(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer","content":"<div>\n<p>(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer's drug aducanumab, making it the first drug cleared by U.S. regulators to slow cognitive decline in...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA approves Biogen's Alzheimer's drug, the first new therapy for the disease in nearly two decades</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA approves Biogen's Alzheimer's drug, the first new therapy for the disease in nearly two decades\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 01:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer's drug aducanumab, making it the first drug cleared by U.S. regulators to slow cognitive decline in...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1108033863","content_text":"(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer's drug aducanumab, making it the first drug cleared by U.S. regulators to slow cognitive decline in people living with Alzheimer's and the first new medicine for the disease in nearly two decades.The FDA's decision was highly anticipated. The drug, which is marketed under the name Aduhelm, is also expected to generate billions of dollars in revenue for the company.\"We are well-aware of the attention surrounding this approval,\" Dr. Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research, said in a press release. \"We understand that Aduhelm has garnered the attention of the press, the Alzheimer's patient community, our elected officials, and other interested stakeholders.\"\"With a treatment for a serious, life-threatening disease in the balance, it makes sense that so many people were following the outcome of this review,\" Cavazzoni added.Alzheimer’s disease is a progressive neurodegenerative disorder that slowly destroys memory and thinking skills. More than 6 million Americans are living with the disease, according toestimates by the Alzheimer’s Association.By 2050, that number is projected to rise to nearly 13 million, according to the group.There were previously no drugs cleared by the FDA that can slow the mental decline from Alzheimer’s, which is the sixth leading cause of death in the United States. The U.S. agency has approved Alzheimer’s drugs aimed at helping symptoms, not actually slowing the disease itself.Federal regulators have faced intense pressure from friends and family members of Alzheimer’s patients asking to fast-track aducanumab, but the road to regulatory approval has been a controversial one since it showed promise in 2016.In March of 2019, Biogen pulled work on the drug after an analysis from an independent group revealed it was unlikely to work. The company then shocked investors several months later by announcing it would seek regulatory approval for the drug after all.Shares of Biogen soared in Novemberafter it won backing from FDA staff, who said the company showed highly “persuasive” evidence aducanumab was effective and that it had “an acceptable safety profile that would support use in individuals with Alzheimer’s disease.”But two days later, a panel of outside experts that advises theU.S. agency unexpectedly declined to endorsethe experimental drug, citing unconvincing data. It also criticized agency staff for what it called an overly positive review.When Biogen sought approval for the drug in late 2019, its scientists said a new analysis of a larger data set showed that aducanumab “reduced clinical decline in patients with early Alzheimer’s disease.”Alzheimer’s experts and Wall Street analysts were immediately skeptical, with some wondering whether the clinical trial data was enough to prove that the drug works and whether approval could make it harder for other companies to enroll patients in their own drug trials.Some doctorshave said they won’t prescribethe drug if it does reach the market, because of the mixed data package supporting the company’s application.Supporters, including advocacy groups and family members of those living with the disease desperate for a new treatment, have acknowledged that the data isn’t perfect. However, they argue that it could help some patients with Alzheimer’s, a progressive and debilitating disease.Biogen’s drug targets a “sticky” compound in the brain known as beta-amyloid, which scientists expect plays a role in the devastating disease. The company has previously estimated about 1.5 million people with early Alzheimer’s in the U.S. could be candidates for the drug, according to Reuters.The FDA decision is expected to reverberate throughout the biopharma sector, RBC Capital Markets analyst Brian Abrahams said in a note to clients on June 1.The U.S. agency said Monday it determined there was “substantial evidence” the drug helps patients.“As a result of FDA’s approval of Aduhelm, patients with Alzheimer’s disease have an important and critical new treatment to help combat this disease,” it said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":354,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":194679065,"gmtCreate":1621380349557,"gmtModify":1634192076375,"author":{"id":"3573681651019306","authorId":"3573681651019306","name":"Waffles_11","avatar":"https://static.tigerbbs.com/9d49a2f6994c90065ccb9ee9e61b94cd","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573681651019306","authorIdStr":"3573681651019306"},"themes":[],"htmlText":"Awesome 👍🏼","listText":"Awesome 👍🏼","text":"Awesome 👍🏼","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/194679065","repostId":"2136994482","repostType":4,"repost":{"id":"2136994482","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1621375200,"share":"https://www.laohu8.com/m/news/2136994482?lang=&edition=full","pubTime":"2021-05-19 06:00","market":"us","language":"en","title":"Trip.com rises 6% as first quarter brings surprise profit, revenue turnaround","url":"https://stock-news.laohu8.com/highlight/detail?id=2136994482","media":"Tiger Newspress","summary":"Trip.com Group Limited (Nasdaq: TCOM and HKEX: 9961) (\"Trip.com Group\" or the \"Company\"), a leading ","content":"<p>Trip.com Group Limited (Nasdaq: TCOM and HKEX: 9961) (\"Trip.com Group\" or the \"Company\"), a leading <a href=\"https://laohu8.com/S/AONE\">one</a>-stop travel service provider of accommodation reservation, transportation ticketing, packaged tours and corporate travel management, today announced its unaudited financial results for the first quarter ended March 31, 2021.</p><p><b>Key Highlights for the First Quarter of 2021</b></p><ul><li>Our business has showed resilient recovery in the China domestic market.</li></ul><p>- Compared with the same period pre-COVID in 2019, both domestic hotel and air ticketing reservations have fully recovered since early March 2021 and achieved double-digit growth for the month.</p><p>- Revenues from corporate travel management grew 101% year-over-year and 6% compared with the same period in 2019.</p><p>\"Trip.com Group's mission is to pursue the perfect trip for a better world. Over the past two decades, we have continuously been exploring and innovating to further expand our offerings,\" said James Liang, Executive Chairman. \"Going forward, we will continue to expand product offerings, improve service quality, innovate our content, and bring new value to the travel industry.\"</p><p>\"Despite the challenges in January and February of 2021 due to outbreaks of virus during the winter season, China domestic travel rebounded quickly in March and showed stronger momentum in April and May,\" said Jane Sun, Chief Executive Officer. \"Quality leisure travel showed rapid growth, with reservations for mid to high-end hotels spearheading growth. Meanwhile, long-distance travel in mainland China has fully recovered, and short-distance travel has shown a continuing growth trajectory.\"</p><p>Trip.com&nbsp;once rose 6% in&nbsp;after&nbsp;hour&nbsp;trading.</p><p><img src=\"https://static.tigerbbs.com/0ab4cd00d93411c4c66300d7da8341b4\" tg-width=\"1287\" tg-height=\"638\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Trip.com rises 6% as first quarter brings surprise profit, revenue turnaround</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTrip.com rises 6% as first quarter brings surprise profit, revenue turnaround\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-05-19 06:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Trip.com Group Limited (Nasdaq: TCOM and HKEX: 9961) (\"Trip.com Group\" or the \"Company\"), a leading <a href=\"https://laohu8.com/S/AONE\">one</a>-stop travel service provider of accommodation reservation, transportation ticketing, packaged tours and corporate travel management, today announced its unaudited financial results for the first quarter ended March 31, 2021.</p><p><b>Key Highlights for the First Quarter of 2021</b></p><ul><li>Our business has showed resilient recovery in the China domestic market.</li></ul><p>- Compared with the same period pre-COVID in 2019, both domestic hotel and air ticketing reservations have fully recovered since early March 2021 and achieved double-digit growth for the month.</p><p>- Revenues from corporate travel management grew 101% year-over-year and 6% compared with the same period in 2019.</p><p>\"Trip.com Group's mission is to pursue the perfect trip for a better world. Over the past two decades, we have continuously been exploring and innovating to further expand our offerings,\" said James Liang, Executive Chairman. \"Going forward, we will continue to expand product offerings, improve service quality, innovate our content, and bring new value to the travel industry.\"</p><p>\"Despite the challenges in January and February of 2021 due to outbreaks of virus during the winter season, China domestic travel rebounded quickly in March and showed stronger momentum in April and May,\" said Jane Sun, Chief Executive Officer. \"Quality leisure travel showed rapid growth, with reservations for mid to high-end hotels spearheading growth. Meanwhile, long-distance travel in mainland China has fully recovered, and short-distance travel has shown a continuing growth trajectory.\"</p><p>Trip.com&nbsp;once rose 6% in&nbsp;after&nbsp;hour&nbsp;trading.</p><p><img src=\"https://static.tigerbbs.com/0ab4cd00d93411c4c66300d7da8341b4\" tg-width=\"1287\" tg-height=\"638\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TCOM":"携程网"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2136994482","content_text":"Trip.com Group Limited (Nasdaq: TCOM and HKEX: 9961) (\"Trip.com Group\" or the \"Company\"), a leading one-stop travel service provider of accommodation reservation, transportation ticketing, packaged tours and corporate travel management, today announced its unaudited financial results for the first quarter ended March 31, 2021.Key Highlights for the First Quarter of 2021Our business has showed resilient recovery in the China domestic market.- Compared with the same period pre-COVID in 2019, both domestic hotel and air ticketing reservations have fully recovered since early March 2021 and achieved double-digit growth for the month.- Revenues from corporate travel management grew 101% year-over-year and 6% compared with the same period in 2019.\"Trip.com Group's mission is to pursue the perfect trip for a better world. Over the past two decades, we have continuously been exploring and innovating to further expand our offerings,\" said James Liang, Executive Chairman. \"Going forward, we will continue to expand product offerings, improve service quality, innovate our content, and bring new value to the travel industry.\"\"Despite the challenges in January and February of 2021 due to outbreaks of virus during the winter season, China domestic travel rebounded quickly in March and showed stronger momentum in April and May,\" said Jane Sun, Chief Executive Officer. \"Quality leisure travel showed rapid growth, with reservations for mid to high-end hotels spearheading growth. Meanwhile, long-distance travel in mainland China has fully recovered, and short-distance travel has shown a continuing growth trajectory.\"Trip.com once rose 6% in after hour trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":551,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":190372280,"gmtCreate":1620603536940,"gmtModify":1634197861912,"author":{"id":"3573681651019306","authorId":"3573681651019306","name":"Waffles_11","avatar":"https://static.tigerbbs.com/9d49a2f6994c90065ccb9ee9e61b94cd","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573681651019306","authorIdStr":"3573681651019306"},"themes":[],"htmlText":"Wow nice 👍🏼&nbsp;","listText":"Wow nice 👍🏼&nbsp;","text":"Wow nice 👍🏼","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/190372280","repostId":"1120563519","repostType":4,"isVote":1,"tweetType":1,"viewCount":404,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":102987941,"gmtCreate":1620173740283,"gmtModify":1634207293868,"author":{"id":"3573681651019306","authorId":"3573681651019306","name":"Waffles_11","avatar":"https://static.tigerbbs.com/9d49a2f6994c90065ccb9ee9e61b94cd","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573681651019306","authorIdStr":"3573681651019306"},"themes":[],"htmlText":":(","listText":":(","text":":(","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/102987941","repostId":"1155693310","repostType":4,"repost":{"id":"1155693310","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1620136027,"share":"https://www.laohu8.com/m/news/1155693310?lang=&edition=full","pubTime":"2021-05-04 21:47","market":"us","language":"en","title":"EV stocks fell in morning trading Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1155693310","media":"Tiger Newspress","summary":"(May 4) EV stocks fell in morning trading.Nio, Xpeng EV Sales Surge But Pace Slows Amid Chip Woes, T","content":"<p>(May 4)&nbsp;EV stocks fell in morning trading.</p><p><img src=\"https://static.tigerbbs.com/fd0d09d1cfb015fcc05b991203469b9d\" tg-width=\"268\" tg-height=\"249\" referrerpolicy=\"no-referrer\"><b>Nio, Xpeng EV Sales Surge But Pace Slows Amid Chip Woes, Tesla Ramping Up</b></p><p><b>Nio</b>(NIO),<b>Xpeng Motors</b>(XPEV) and<b>Li Auto</b>(LI) all grew April sales triple digits on home turf despite a chip shortage that idled a Nio factory for a few days. Sales slowed for the trio of Chinese EV startups vs. March's pace, as<b>Tesla</b>(TSLA) ramps up competition.</p><p>Nio stock reversed slightly Monday, while Xpeng and Li Auto also&nbsp; fell.</p><p>Year over year, Nio's April sales jumped 125% to 5,147 electric vehicles. That included 1,523 seven-seater ES8 SUVs, 3,163 five-seater ES6 SUVs, and 2,416 EC6 electric crossovers.</p><p>Sales growth slowed from the 373% pace that Nio saw in March.</p><p>But Nio's April EV sales defied the chip shortage that forced the emerging Tesla of China to temporarily suspend factory production for five days starting March 29.</p><p>Year over year, Xpeng Motors saw April sales surge 285% to 5,147 electric vehicles. That included 2,995 P7 sedans and 2,152 G3 compact SUVs.</p><p>However, growth slowed from March's 384% pace.</p><p>Year over year, Li Auto's April sales increased 111% to 5,539 hybrid-electric SUVs. Sales growth slowed from March's 239% pace.</p><p>Li Auto reached a milestone 500,000th delivery faster than any of its peers, the Chinese EV startup said in a statement.</p><p>Month to month, Nio sales fell 2.1%. Nio last week indicated that Q2 deliveries would roughly flat vs. Q1 amid chip shortages. Xpeng sales rose 1% vs. March. Li Auto sales climbed 13% vs. the prior month.</p><p>Nio Stock, Xpeng Stock</p><p>Shares of Nio fell 0.75% to 39.54 on thestock market Monday&nbsp;after hitting 41.45 intraday. Nio stock has been meeting resistance at the 50-day line after bouncing off the 200-day line in mid-April. Xpeng stock fell 3% and hasn't traded above the 50-day line since February. Li Auto lost 1.5%.</p><p>All three EV stocks remain in a severe bear market on a multitude of factors, including rising competition in China. Tesla, which dominates the Chinese market for luxury EVs, began selling a locally made Model Y SUV this year.</p><p>Tesla stock slumped 3.5% amid a report that the key Berlin plant won't start production until 2022. Shares closed just above their declining 50-day line. TSLA stock rebounded above the 50-day line on Friday, after tumbling more than 8% in the three days after the EV maker's earnings.</p><p>China EV Competition Heats Up</p><p>After booming sales in 2020, Nio and Xpeng face tougher competition ahead. Tesla officially launched the new made-in-Shanghai Model Y crossover Jan. 1, a rival to Nio's EC6 and Xpeng's G7, and is ramping up sales. It already sold a locally made Model 3 sedan in China.</p><p>Traditional auto giants are ramping up EV plans in China.<b>Volkswagen</b>(VWAGY) began deliveries of its made-in-China ID.4 crossover in late March.<b>Ford</b>(F) is taking preorders for Mach-E crossover, which is beginning local production.</p><p>Last month, Tesla hiked prices of made-in-China Model Y SUVs. The price increase signaled that Tesla is \"comfortable\" with sales of its newest EV for the Chinese market, local reports said.</p><p>As Tesla rises, Nio and its China EV stock peers all plan to introduce new, more attractively priced EVs. Last month,Xpeng showed off a smaller electric sedanthat it touts as the world's first mass-produced EV with lidar sensors.</p><p>According to Wedbush analysts, \"China remains a greenfield EV market opportunity as we believe EV sales can potentially double in the region over the next few years.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV stocks fell in morning trading Tuesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV stocks fell in morning trading Tuesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-05-04 21:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(May 4)&nbsp;EV stocks fell in morning trading.</p><p><img src=\"https://static.tigerbbs.com/fd0d09d1cfb015fcc05b991203469b9d\" tg-width=\"268\" tg-height=\"249\" referrerpolicy=\"no-referrer\"><b>Nio, Xpeng EV Sales Surge But Pace Slows Amid Chip Woes, Tesla Ramping Up</b></p><p><b>Nio</b>(NIO),<b>Xpeng Motors</b>(XPEV) and<b>Li Auto</b>(LI) all grew April sales triple digits on home turf despite a chip shortage that idled a Nio factory for a few days. Sales slowed for the trio of Chinese EV startups vs. March's pace, as<b>Tesla</b>(TSLA) ramps up competition.</p><p>Nio stock reversed slightly Monday, while Xpeng and Li Auto also&nbsp; fell.</p><p>Year over year, Nio's April sales jumped 125% to 5,147 electric vehicles. That included 1,523 seven-seater ES8 SUVs, 3,163 five-seater ES6 SUVs, and 2,416 EC6 electric crossovers.</p><p>Sales growth slowed from the 373% pace that Nio saw in March.</p><p>But Nio's April EV sales defied the chip shortage that forced the emerging Tesla of China to temporarily suspend factory production for five days starting March 29.</p><p>Year over year, Xpeng Motors saw April sales surge 285% to 5,147 electric vehicles. That included 2,995 P7 sedans and 2,152 G3 compact SUVs.</p><p>However, growth slowed from March's 384% pace.</p><p>Year over year, Li Auto's April sales increased 111% to 5,539 hybrid-electric SUVs. Sales growth slowed from March's 239% pace.</p><p>Li Auto reached a milestone 500,000th delivery faster than any of its peers, the Chinese EV startup said in a statement.</p><p>Month to month, Nio sales fell 2.1%. Nio last week indicated that Q2 deliveries would roughly flat vs. Q1 amid chip shortages. Xpeng sales rose 1% vs. March. Li Auto sales climbed 13% vs. the prior month.</p><p>Nio Stock, Xpeng Stock</p><p>Shares of Nio fell 0.75% to 39.54 on thestock market Monday&nbsp;after hitting 41.45 intraday. Nio stock has been meeting resistance at the 50-day line after bouncing off the 200-day line in mid-April. Xpeng stock fell 3% and hasn't traded above the 50-day line since February. Li Auto lost 1.5%.</p><p>All three EV stocks remain in a severe bear market on a multitude of factors, including rising competition in China. Tesla, which dominates the Chinese market for luxury EVs, began selling a locally made Model Y SUV this year.</p><p>Tesla stock slumped 3.5% amid a report that the key Berlin plant won't start production until 2022. Shares closed just above their declining 50-day line. TSLA stock rebounded above the 50-day line on Friday, after tumbling more than 8% in the three days after the EV maker's earnings.</p><p>China EV Competition Heats Up</p><p>After booming sales in 2020, Nio and Xpeng face tougher competition ahead. Tesla officially launched the new made-in-Shanghai Model Y crossover Jan. 1, a rival to Nio's EC6 and Xpeng's G7, and is ramping up sales. It already sold a locally made Model 3 sedan in China.</p><p>Traditional auto giants are ramping up EV plans in China.<b>Volkswagen</b>(VWAGY) began deliveries of its made-in-China ID.4 crossover in late March.<b>Ford</b>(F) is taking preorders for Mach-E crossover, which is beginning local production.</p><p>Last month, Tesla hiked prices of made-in-China Model Y SUVs. The price increase signaled that Tesla is \"comfortable\" with sales of its newest EV for the Chinese market, local reports said.</p><p>As Tesla rises, Nio and its China EV stock peers all plan to introduce new, more attractively priced EVs. Last month,Xpeng showed off a smaller electric sedanthat it touts as the world's first mass-produced EV with lidar sensors.</p><p>According to Wedbush analysts, \"China remains a greenfield EV market opportunity as we believe EV sales can potentially double in the region over the next few years.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉","XPEV":"小鹏汽车","LI":"理想汽车","NIO":"蔚来"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1155693310","content_text":"(May 4) EV stocks fell in morning trading.Nio, Xpeng EV Sales Surge But Pace Slows Amid Chip Woes, Tesla Ramping UpNio(NIO),Xpeng Motors(XPEV) andLi Auto(LI) all grew April sales triple digits on home turf despite a chip shortage that idled a Nio factory for a few days. Sales slowed for the trio of Chinese EV startups vs. March's pace, asTesla(TSLA) ramps up competition.Nio stock reversed slightly Monday, while Xpeng and Li Auto also  fell.Year over year, Nio's April sales jumped 125% to 5,147 electric vehicles. That included 1,523 seven-seater ES8 SUVs, 3,163 five-seater ES6 SUVs, and 2,416 EC6 electric crossovers.Sales growth slowed from the 373% pace that Nio saw in March.But Nio's April EV sales defied the chip shortage that forced the emerging Tesla of China to temporarily suspend factory production for five days starting March 29.Year over year, Xpeng Motors saw April sales surge 285% to 5,147 electric vehicles. That included 2,995 P7 sedans and 2,152 G3 compact SUVs.However, growth slowed from March's 384% pace.Year over year, Li Auto's April sales increased 111% to 5,539 hybrid-electric SUVs. Sales growth slowed from March's 239% pace.Li Auto reached a milestone 500,000th delivery faster than any of its peers, the Chinese EV startup said in a statement.Month to month, Nio sales fell 2.1%. Nio last week indicated that Q2 deliveries would roughly flat vs. Q1 amid chip shortages. Xpeng sales rose 1% vs. March. Li Auto sales climbed 13% vs. the prior month.Nio Stock, Xpeng StockShares of Nio fell 0.75% to 39.54 on thestock market Monday after hitting 41.45 intraday. Nio stock has been meeting resistance at the 50-day line after bouncing off the 200-day line in mid-April. Xpeng stock fell 3% and hasn't traded above the 50-day line since February. Li Auto lost 1.5%.All three EV stocks remain in a severe bear market on a multitude of factors, including rising competition in China. Tesla, which dominates the Chinese market for luxury EVs, began selling a locally made Model Y SUV this year.Tesla stock slumped 3.5% amid a report that the key Berlin plant won't start production until 2022. Shares closed just above their declining 50-day line. TSLA stock rebounded above the 50-day line on Friday, after tumbling more than 8% in the three days after the EV maker's earnings.China EV Competition Heats UpAfter booming sales in 2020, Nio and Xpeng face tougher competition ahead. Tesla officially launched the new made-in-Shanghai Model Y crossover Jan. 1, a rival to Nio's EC6 and Xpeng's G7, and is ramping up sales. It already sold a locally made Model 3 sedan in China.Traditional auto giants are ramping up EV plans in China.Volkswagen(VWAGY) began deliveries of its made-in-China ID.4 crossover in late March.Ford(F) is taking preorders for Mach-E crossover, which is beginning local production.Last month, Tesla hiked prices of made-in-China Model Y SUVs. The price increase signaled that Tesla is \"comfortable\" with sales of its newest EV for the Chinese market, local reports said.As Tesla rises, Nio and its China EV stock peers all plan to introduce new, more attractively priced EVs. Last month,Xpeng showed off a smaller electric sedanthat it touts as the world's first mass-produced EV with lidar sensors.According to Wedbush analysts, \"China remains a greenfield EV market opportunity as we believe EV sales can potentially double in the region over the next few years.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":280,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":103173796,"gmtCreate":1619761120015,"gmtModify":1634210101226,"author":{"id":"3573681651019306","authorId":"3573681651019306","name":"Waffles_11","avatar":"https://static.tigerbbs.com/9d49a2f6994c90065ccb9ee9e61b94cd","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573681651019306","authorIdStr":"3573681651019306"},"themes":[],"htmlText":"That's awesome!&nbsp;","listText":"That's awesome!&nbsp;","text":"That's awesome!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/103173796","repostId":"1153490597","repostType":4,"repost":{"id":"1153490597","kind":"news","pubTimestamp":1619741154,"share":"https://www.laohu8.com/m/news/1153490597?lang=&edition=full","pubTime":"2021-04-30 08:05","market":"us","language":"en","title":"S&P 500 notches record close after strong earnings from Facebook and Apple","url":"https://stock-news.laohu8.com/highlight/detail?id=1153490597","media":"CNBC","summary":"The S&P 500 closed at record levels on Thursday after blowout earnings results from two of the biggest tech companies in the world: Apple and Facebook.The Dow Jones Industrial Average ended the day up 239.98 points, or 0.7%, at 34,060.36. The S&P 500 advanced just under 0.7% to finish the day at 4,211.47, a new closing high.The tech-heavy Nasdaq Composite, which began the day up 1%, underperformed with a gain of just over 0.2% to end the session at 14,082.55.Apple, which reported earnings yester","content":"<div>\n<p>The S&P 500 closed at record levels on Thursday after blowout earnings results from two of the biggest tech companies in the world: Apple and Facebook.The Dow Jones Industrial Average ended the day up...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/28/stock-market-futures-open-to-close-news.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>S&P 500 notches record close after strong earnings from Facebook and Apple</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nS&P 500 notches record close after strong earnings from Facebook and Apple\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-30 08:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/04/28/stock-market-futures-open-to-close-news.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The S&P 500 closed at record levels on Thursday after blowout earnings results from two of the biggest tech companies in the world: Apple and Facebook.The Dow Jones Industrial Average ended the day up...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/28/stock-market-futures-open-to-close-news.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯","TWTR":"Twitter","AAPL":"苹果",".IXIC":"NASDAQ Composite"},"source_url":"https://www.cnbc.com/2021/04/28/stock-market-futures-open-to-close-news.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1153490597","content_text":"The S&P 500 closed at record levels on Thursday after blowout earnings results from two of the biggest tech companies in the world: Apple and Facebook.The Dow Jones Industrial Average ended the day up 239.98 points, or 0.7%, at 34,060.36. The S&P 500 advanced just under 0.7% to finish the day at 4,211.47, a new closing high.The tech-heavy Nasdaq Composite, which began the day up 1%, underperformed with a gain of just over 0.2% to end the session at 14,082.55.Apple, which reported earnings yesterday afternoon, said that sales jumped 54% during the quarter, with each product category seeing double-digit growth. The company also said it would increase its dividend by 7%, and authorized $90 billion in share buybacks. Still, Apple shares ended the day just under the flatline.“The primary market trend remains positive,” said Keith Lerner, chief market strategist at Truist. “But we expect a choppier environment as tensions are set to persist between better economic growth and earnings prospects versus the potential for higher taxes and rising interest rates as the economy normalizes,” he added.Thursday marks President Joe Biden’s 100th day in office. On Wednesday evening, he made his first address to a joint session of Congress where he pushed his so-far popular agenda, which includes a $2 trillion infrastructure plan as well as a freshly unveiled, $1.8 trillion plan for families, children and students.Thursday is also the busiest day of the quarterly earnings season, with roughly 11% of the S&P 500 slated to provide quarterly updates.McDonald’s published its results before the opening bell and told investors that its sales have finally topped pre-pandemic levels. The Dow component also raised its outlook for systemwide sales growth. The stock added 1.2% at the close.Caterpillar, which also reported on Thursday, lost 2% while Merck dropped 4.4% following disappointing results. Amazon issued its first-quarter results shortlyafter market close. The e-commerce giant surpassed analysts’ expectations on earnings and revenue.Gilead Sciences, Twitter, U.S. Steel and Western Digital will also post results after the bell.Facebook’s revenue jumped 48%, driven by higher-priced ads, sending its stock up 7.3% and to a record. Qualcomm shares added 4.4% after reporting a 52% jump in revenue.Economic data released Thursday gave investors an update on the progress of the economic recovery.First-quarter GDP hit an annualized rate of 6.4%, according to a report published by the Bureau of Economic Analysis, a sign that the U.S. economy began 2021 with an accelerationof commercial activity. Outside of the reopening-fueled third-quarter surge last year, it was the best period for GDP since the third quarter of 2003.The Labor Department, meanwhile, reported that initial jobless claims last week totaled 553,000, just above the 528,000 estimate issued by Dow Jones.The Federal Reserve said Wednesday that it would hold interest rates near zero. The S&P slid from its high after Federal Reserve Chairman Jerome Powell said during a press conference following the Federal Open Market Committee’s decision that there are some signs of froth in the market.“Rates remain unchanged for now and, despite improving economic data, taper talk remained off the table at today’s Federal Reserve meeting,” said Bethany Payne, portfolio manager at Janus Henderson.“As vaccination rates accelerate, employment strengthens, and expansive fiscal policy adds further support to household and business incomes, investors are now looking for signs of whether the central bank safety net could be withdrawn sooner than expected,” she added.Big Tech earningsAmazon sales surge 44% as it smashes earnings expectationsNio Reports Q1 Beat Amid Strong Demand, Forecasts Deliveries Growth Despite Chip ShortagesTwitter stock plunges on user miss and low guidanceWestern Digital's quarterly results and outlook topped Wall Street estimatesGilead Sciences Q1 Earnings Beat EstimatesWireless-Chip Maker Skyworks Squeaks By Second-Quarter TargetsDexCom Surpasses Q1 Earnings and Revenue EstimatesUnited States Steel Q1 Earnings Surpass Estimates","news_type":1},"isVote":1,"tweetType":1,"viewCount":320,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":103054534,"gmtCreate":1619740501228,"gmtModify":1634210330968,"author":{"id":"3573681651019306","authorId":"3573681651019306","name":"Waffles_11","avatar":"https://static.tigerbbs.com/9d49a2f6994c90065ccb9ee9e61b94cd","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573681651019306","authorIdStr":"3573681651019306"},"themes":[],"htmlText":"Wow nice 👍🏼","listText":"Wow nice 👍🏼","text":"Wow nice 👍🏼","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/103054534","repostId":"2131534297","repostType":4,"isVote":1,"tweetType":1,"viewCount":619,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":103053612,"gmtCreate":1619740273136,"gmtModify":1634210336239,"author":{"id":"3573681651019306","authorId":"3573681651019306","name":"Waffles_11","avatar":"https://static.tigerbbs.com/9d49a2f6994c90065ccb9ee9e61b94cd","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573681651019306","authorIdStr":"3573681651019306"},"themes":[],"htmlText":"Wow awesome&nbsp;","listText":"Wow awesome&nbsp;","text":"Wow awesome","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/103053612","repostId":"1161815718","repostType":4,"isVote":1,"tweetType":1,"viewCount":267,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":194679065,"gmtCreate":1621380349557,"gmtModify":1634192076375,"author":{"id":"3573681651019306","authorId":"3573681651019306","name":"Waffles_11","avatar":"https://static.tigerbbs.com/9d49a2f6994c90065ccb9ee9e61b94cd","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573681651019306","idStr":"3573681651019306"},"themes":[],"htmlText":"Awesome 👍🏼","listText":"Awesome 👍🏼","text":"Awesome 👍🏼","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/194679065","repostId":"2136994482","repostType":4,"isVote":1,"tweetType":1,"viewCount":551,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":103054534,"gmtCreate":1619740501228,"gmtModify":1634210330968,"author":{"id":"3573681651019306","authorId":"3573681651019306","name":"Waffles_11","avatar":"https://static.tigerbbs.com/9d49a2f6994c90065ccb9ee9e61b94cd","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573681651019306","idStr":"3573681651019306"},"themes":[],"htmlText":"Wow nice 👍🏼","listText":"Wow nice 👍🏼","text":"Wow nice 👍🏼","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/103054534","repostId":"2131534297","repostType":4,"isVote":1,"tweetType":1,"viewCount":619,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":114783406,"gmtCreate":1623106245705,"gmtModify":1634037017242,"author":{"id":"3573681651019306","authorId":"3573681651019306","name":"Waffles_11","avatar":"https://static.tigerbbs.com/9d49a2f6994c90065ccb9ee9e61b94cd","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573681651019306","idStr":"3573681651019306"},"themes":[],"htmlText":"👍🏼","listText":"👍🏼","text":"👍🏼","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/114783406","repostId":"1108033863","repostType":4,"repost":{"id":"1108033863","kind":"news","pubTimestamp":1623087360,"share":"https://www.laohu8.com/m/news/1108033863?lang=&edition=full","pubTime":"2021-06-08 01:36","market":"us","language":"en","title":"FDA approves Biogen's Alzheimer's drug, the first new therapy for the disease in nearly two decades","url":"https://stock-news.laohu8.com/highlight/detail?id=1108033863","media":"cnbc","summary":"(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer","content":"<div>\n<p>(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer's drug aducanumab, making it the first drug cleared by U.S. regulators to slow cognitive decline in...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA approves Biogen's Alzheimer's drug, the first new therapy for the disease in nearly two decades</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA approves Biogen's Alzheimer's drug, the first new therapy for the disease in nearly two decades\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-08 01:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html><strong>cnbc</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer's drug aducanumab, making it the first drug cleared by U.S. regulators to slow cognitive decline in...</p>\n\n<a href=\"https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.cnbc.com/2021/06/07/fda-approves-biogens-alzheimers-drug-the-first-new-therapy-for-the-disease-in-nearly-two-decades.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1108033863","content_text":"(June 7) Biogen surged nearly 60%.The Food and Drug Administration on Monday approvedBiogenAlzheimer's drug aducanumab, making it the first drug cleared by U.S. regulators to slow cognitive decline in people living with Alzheimer's and the first new medicine for the disease in nearly two decades.The FDA's decision was highly anticipated. The drug, which is marketed under the name Aduhelm, is also expected to generate billions of dollars in revenue for the company.\"We are well-aware of the attention surrounding this approval,\" Dr. Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research, said in a press release. \"We understand that Aduhelm has garnered the attention of the press, the Alzheimer's patient community, our elected officials, and other interested stakeholders.\"\"With a treatment for a serious, life-threatening disease in the balance, it makes sense that so many people were following the outcome of this review,\" Cavazzoni added.Alzheimer’s disease is a progressive neurodegenerative disorder that slowly destroys memory and thinking skills. More than 6 million Americans are living with the disease, according toestimates by the Alzheimer’s Association.By 2050, that number is projected to rise to nearly 13 million, according to the group.There were previously no drugs cleared by the FDA that can slow the mental decline from Alzheimer’s, which is the sixth leading cause of death in the United States. The U.S. agency has approved Alzheimer’s drugs aimed at helping symptoms, not actually slowing the disease itself.Federal regulators have faced intense pressure from friends and family members of Alzheimer’s patients asking to fast-track aducanumab, but the road to regulatory approval has been a controversial one since it showed promise in 2016.In March of 2019, Biogen pulled work on the drug after an analysis from an independent group revealed it was unlikely to work. The company then shocked investors several months later by announcing it would seek regulatory approval for the drug after all.Shares of Biogen soared in Novemberafter it won backing from FDA staff, who said the company showed highly “persuasive” evidence aducanumab was effective and that it had “an acceptable safety profile that would support use in individuals with Alzheimer’s disease.”But two days later, a panel of outside experts that advises theU.S. agency unexpectedly declined to endorsethe experimental drug, citing unconvincing data. It also criticized agency staff for what it called an overly positive review.When Biogen sought approval for the drug in late 2019, its scientists said a new analysis of a larger data set showed that aducanumab “reduced clinical decline in patients with early Alzheimer’s disease.”Alzheimer’s experts and Wall Street analysts were immediately skeptical, with some wondering whether the clinical trial data was enough to prove that the drug works and whether approval could make it harder for other companies to enroll patients in their own drug trials.Some doctorshave said they won’t prescribethe drug if it does reach the market, because of the mixed data package supporting the company’s application.Supporters, including advocacy groups and family members of those living with the disease desperate for a new treatment, have acknowledged that the data isn’t perfect. However, they argue that it could help some patients with Alzheimer’s, a progressive and debilitating disease.Biogen’s drug targets a “sticky” compound in the brain known as beta-amyloid, which scientists expect plays a role in the devastating disease. The company has previously estimated about 1.5 million people with early Alzheimer’s in the U.S. could be candidates for the drug, according to Reuters.The FDA decision is expected to reverberate throughout the biopharma sector, RBC Capital Markets analyst Brian Abrahams said in a note to clients on June 1.The U.S. agency said Monday it determined there was “substantial evidence” the drug helps patients.“As a result of FDA’s approval of Aduhelm, patients with Alzheimer’s disease have an important and critical new treatment to help combat this disease,” it said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":354,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":103173796,"gmtCreate":1619761120015,"gmtModify":1634210101226,"author":{"id":"3573681651019306","authorId":"3573681651019306","name":"Waffles_11","avatar":"https://static.tigerbbs.com/9d49a2f6994c90065ccb9ee9e61b94cd","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573681651019306","idStr":"3573681651019306"},"themes":[],"htmlText":"That's awesome!&nbsp;","listText":"That's awesome!&nbsp;","text":"That's awesome!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/103173796","repostId":"1153490597","repostType":4,"isVote":1,"tweetType":1,"viewCount":320,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":165625964,"gmtCreate":1624134788658,"gmtModify":1634010452276,"author":{"id":"3573681651019306","authorId":"3573681651019306","name":"Waffles_11","avatar":"https://static.tigerbbs.com/9d49a2f6994c90065ccb9ee9e61b94cd","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573681651019306","idStr":"3573681651019306"},"themes":[],"htmlText":"Good read&nbsp;","listText":"Good read&nbsp;","text":"Good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/165625964","repostId":"1161408410","repostType":4,"isVote":1,"tweetType":1,"viewCount":205,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":162158121,"gmtCreate":1624048076563,"gmtModify":1634023616440,"author":{"id":"3573681651019306","authorId":"3573681651019306","name":"Waffles_11","avatar":"https://static.tigerbbs.com/9d49a2f6994c90065ccb9ee9e61b94cd","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573681651019306","idStr":"3573681651019306"},"themes":[],"htmlText":"Nice awesome&nbsp;","listText":"Nice awesome&nbsp;","text":"Nice awesome","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/162158121","repostId":"2144775875","repostType":4,"isVote":1,"tweetType":1,"viewCount":246,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":190372280,"gmtCreate":1620603536940,"gmtModify":1634197861912,"author":{"id":"3573681651019306","authorId":"3573681651019306","name":"Waffles_11","avatar":"https://static.tigerbbs.com/9d49a2f6994c90065ccb9ee9e61b94cd","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573681651019306","idStr":"3573681651019306"},"themes":[],"htmlText":"Wow nice 👍🏼&nbsp;","listText":"Wow nice 👍🏼&nbsp;","text":"Wow nice 👍🏼","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/190372280","repostId":"1120563519","repostType":4,"repost":{"id":"1120563519","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1620445920,"share":"https://www.laohu8.com/m/news/1120563519?lang=&edition=full","pubTime":"2021-05-08 11:52","market":"us","language":"en","title":"Tesla Raises China Model 3 Prices, Citing Cost Fluctuations","url":"https://stock-news.laohu8.com/highlight/detail?id=1120563519","media":"Tiger Newspress","summary":"Tesla Inc.raised the price of a Model 3 sedan in China by 1,000 yuan ($155) from Saturday, citing co","content":"<p>Tesla Inc.raised the price of a Model 3 sedan in <a href=\"https://laohu8.com/S/CAAS\">China</a> by 1,000 yuan ($155) from Saturday, citing cost fluctuations.</p><p>The basic model of the vehicle is now priced at 250,900 yuan, the automaker said in aposton its <a href=\"https://laohu8.com/S/WB\">Weibo</a> social media account.</p><p>China’sinflationis generally under control, The Economic Daily reported Friday, citing an official from the <a href=\"https://laohu8.com/S/NHLD\">National</a> Bureau of Statistics.<img src=\"https://static.tigerbbs.com/aedaee7c79ea684b08f11620857e02a7\" tg-width=\"741\" tg-height=\"336\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Raises China Model 3 Prices, Citing Cost Fluctuations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Raises China Model 3 Prices, Citing Cost Fluctuations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-05-08 11:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tesla Inc.raised the price of a Model 3 sedan in <a href=\"https://laohu8.com/S/CAAS\">China</a> by 1,000 yuan ($155) from Saturday, citing cost fluctuations.</p><p>The basic model of the vehicle is now priced at 250,900 yuan, the automaker said in aposton its <a href=\"https://laohu8.com/S/WB\">Weibo</a> social media account.</p><p>China’sinflationis generally under control, The Economic Daily reported Friday, citing an official from the <a href=\"https://laohu8.com/S/NHLD\">National</a> Bureau of Statistics.<img src=\"https://static.tigerbbs.com/aedaee7c79ea684b08f11620857e02a7\" tg-width=\"741\" tg-height=\"336\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉","CAAS":"中汽系统"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1120563519","content_text":"Tesla Inc.raised the price of a Model 3 sedan in China by 1,000 yuan ($155) from Saturday, citing cost fluctuations.The basic model of the vehicle is now priced at 250,900 yuan, the automaker said in aposton its Weibo social media account.China’sinflationis generally under control, The Economic Daily reported Friday, citing an official from the National Bureau of Statistics.","news_type":1},"isVote":1,"tweetType":1,"viewCount":404,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":102987941,"gmtCreate":1620173740283,"gmtModify":1634207293868,"author":{"id":"3573681651019306","authorId":"3573681651019306","name":"Waffles_11","avatar":"https://static.tigerbbs.com/9d49a2f6994c90065ccb9ee9e61b94cd","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573681651019306","idStr":"3573681651019306"},"themes":[],"htmlText":":(","listText":":(","text":":(","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/102987941","repostId":"1155693310","repostType":4,"repost":{"id":"1155693310","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1620136027,"share":"https://www.laohu8.com/m/news/1155693310?lang=&edition=full","pubTime":"2021-05-04 21:47","market":"us","language":"en","title":"EV stocks fell in morning trading Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1155693310","media":"Tiger Newspress","summary":"(May 4) EV stocks fell in morning trading.Nio, Xpeng EV Sales Surge But Pace Slows Amid Chip Woes, T","content":"<p>(May 4)&nbsp;EV stocks fell in morning trading.</p><p><img src=\"https://static.tigerbbs.com/fd0d09d1cfb015fcc05b991203469b9d\" tg-width=\"268\" tg-height=\"249\" referrerpolicy=\"no-referrer\"><b>Nio, Xpeng EV Sales Surge But Pace Slows Amid Chip Woes, Tesla Ramping Up</b></p><p><b>Nio</b>(NIO),<b>Xpeng Motors</b>(XPEV) and<b>Li Auto</b>(LI) all grew April sales triple digits on home turf despite a chip shortage that idled a Nio factory for a few days. Sales slowed for the trio of Chinese EV startups vs. March's pace, as<b>Tesla</b>(TSLA) ramps up competition.</p><p>Nio stock reversed slightly Monday, while Xpeng and Li Auto also&nbsp; fell.</p><p>Year over year, Nio's April sales jumped 125% to 5,147 electric vehicles. That included 1,523 seven-seater ES8 SUVs, 3,163 five-seater ES6 SUVs, and 2,416 EC6 electric crossovers.</p><p>Sales growth slowed from the 373% pace that Nio saw in March.</p><p>But Nio's April EV sales defied the chip shortage that forced the emerging Tesla of China to temporarily suspend factory production for five days starting March 29.</p><p>Year over year, Xpeng Motors saw April sales surge 285% to 5,147 electric vehicles. That included 2,995 P7 sedans and 2,152 G3 compact SUVs.</p><p>However, growth slowed from March's 384% pace.</p><p>Year over year, Li Auto's April sales increased 111% to 5,539 hybrid-electric SUVs. Sales growth slowed from March's 239% pace.</p><p>Li Auto reached a milestone 500,000th delivery faster than any of its peers, the Chinese EV startup said in a statement.</p><p>Month to month, Nio sales fell 2.1%. Nio last week indicated that Q2 deliveries would roughly flat vs. Q1 amid chip shortages. Xpeng sales rose 1% vs. March. Li Auto sales climbed 13% vs. the prior month.</p><p>Nio Stock, Xpeng Stock</p><p>Shares of Nio fell 0.75% to 39.54 on thestock market Monday&nbsp;after hitting 41.45 intraday. Nio stock has been meeting resistance at the 50-day line after bouncing off the 200-day line in mid-April. Xpeng stock fell 3% and hasn't traded above the 50-day line since February. Li Auto lost 1.5%.</p><p>All three EV stocks remain in a severe bear market on a multitude of factors, including rising competition in China. Tesla, which dominates the Chinese market for luxury EVs, began selling a locally made Model Y SUV this year.</p><p>Tesla stock slumped 3.5% amid a report that the key Berlin plant won't start production until 2022. Shares closed just above their declining 50-day line. TSLA stock rebounded above the 50-day line on Friday, after tumbling more than 8% in the three days after the EV maker's earnings.</p><p>China EV Competition Heats Up</p><p>After booming sales in 2020, Nio and Xpeng face tougher competition ahead. Tesla officially launched the new made-in-Shanghai Model Y crossover Jan. 1, a rival to Nio's EC6 and Xpeng's G7, and is ramping up sales. It already sold a locally made Model 3 sedan in China.</p><p>Traditional auto giants are ramping up EV plans in China.<b>Volkswagen</b>(VWAGY) began deliveries of its made-in-China ID.4 crossover in late March.<b>Ford</b>(F) is taking preorders for Mach-E crossover, which is beginning local production.</p><p>Last month, Tesla hiked prices of made-in-China Model Y SUVs. The price increase signaled that Tesla is \"comfortable\" with sales of its newest EV for the Chinese market, local reports said.</p><p>As Tesla rises, Nio and its China EV stock peers all plan to introduce new, more attractively priced EVs. Last month,Xpeng showed off a smaller electric sedanthat it touts as the world's first mass-produced EV with lidar sensors.</p><p>According to Wedbush analysts, \"China remains a greenfield EV market opportunity as we believe EV sales can potentially double in the region over the next few years.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EV stocks fell in morning trading Tuesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEV stocks fell in morning trading Tuesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-05-04 21:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>(May 4)&nbsp;EV stocks fell in morning trading.</p><p><img src=\"https://static.tigerbbs.com/fd0d09d1cfb015fcc05b991203469b9d\" tg-width=\"268\" tg-height=\"249\" referrerpolicy=\"no-referrer\"><b>Nio, Xpeng EV Sales Surge But Pace Slows Amid Chip Woes, Tesla Ramping Up</b></p><p><b>Nio</b>(NIO),<b>Xpeng Motors</b>(XPEV) and<b>Li Auto</b>(LI) all grew April sales triple digits on home turf despite a chip shortage that idled a Nio factory for a few days. Sales slowed for the trio of Chinese EV startups vs. March's pace, as<b>Tesla</b>(TSLA) ramps up competition.</p><p>Nio stock reversed slightly Monday, while Xpeng and Li Auto also&nbsp; fell.</p><p>Year over year, Nio's April sales jumped 125% to 5,147 electric vehicles. That included 1,523 seven-seater ES8 SUVs, 3,163 five-seater ES6 SUVs, and 2,416 EC6 electric crossovers.</p><p>Sales growth slowed from the 373% pace that Nio saw in March.</p><p>But Nio's April EV sales defied the chip shortage that forced the emerging Tesla of China to temporarily suspend factory production for five days starting March 29.</p><p>Year over year, Xpeng Motors saw April sales surge 285% to 5,147 electric vehicles. That included 2,995 P7 sedans and 2,152 G3 compact SUVs.</p><p>However, growth slowed from March's 384% pace.</p><p>Year over year, Li Auto's April sales increased 111% to 5,539 hybrid-electric SUVs. Sales growth slowed from March's 239% pace.</p><p>Li Auto reached a milestone 500,000th delivery faster than any of its peers, the Chinese EV startup said in a statement.</p><p>Month to month, Nio sales fell 2.1%. Nio last week indicated that Q2 deliveries would roughly flat vs. Q1 amid chip shortages. Xpeng sales rose 1% vs. March. Li Auto sales climbed 13% vs. the prior month.</p><p>Nio Stock, Xpeng Stock</p><p>Shares of Nio fell 0.75% to 39.54 on thestock market Monday&nbsp;after hitting 41.45 intraday. Nio stock has been meeting resistance at the 50-day line after bouncing off the 200-day line in mid-April. Xpeng stock fell 3% and hasn't traded above the 50-day line since February. Li Auto lost 1.5%.</p><p>All three EV stocks remain in a severe bear market on a multitude of factors, including rising competition in China. Tesla, which dominates the Chinese market for luxury EVs, began selling a locally made Model Y SUV this year.</p><p>Tesla stock slumped 3.5% amid a report that the key Berlin plant won't start production until 2022. Shares closed just above their declining 50-day line. TSLA stock rebounded above the 50-day line on Friday, after tumbling more than 8% in the three days after the EV maker's earnings.</p><p>China EV Competition Heats Up</p><p>After booming sales in 2020, Nio and Xpeng face tougher competition ahead. Tesla officially launched the new made-in-Shanghai Model Y crossover Jan. 1, a rival to Nio's EC6 and Xpeng's G7, and is ramping up sales. It already sold a locally made Model 3 sedan in China.</p><p>Traditional auto giants are ramping up EV plans in China.<b>Volkswagen</b>(VWAGY) began deliveries of its made-in-China ID.4 crossover in late March.<b>Ford</b>(F) is taking preorders for Mach-E crossover, which is beginning local production.</p><p>Last month, Tesla hiked prices of made-in-China Model Y SUVs. The price increase signaled that Tesla is \"comfortable\" with sales of its newest EV for the Chinese market, local reports said.</p><p>As Tesla rises, Nio and its China EV stock peers all plan to introduce new, more attractively priced EVs. Last month,Xpeng showed off a smaller electric sedanthat it touts as the world's first mass-produced EV with lidar sensors.</p><p>According to Wedbush analysts, \"China remains a greenfield EV market opportunity as we believe EV sales can potentially double in the region over the next few years.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉","XPEV":"小鹏汽车","LI":"理想汽车","NIO":"蔚来"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1155693310","content_text":"(May 4) EV stocks fell in morning trading.Nio, Xpeng EV Sales Surge But Pace Slows Amid Chip Woes, Tesla Ramping UpNio(NIO),Xpeng Motors(XPEV) andLi Auto(LI) all grew April sales triple digits on home turf despite a chip shortage that idled a Nio factory for a few days. Sales slowed for the trio of Chinese EV startups vs. March's pace, asTesla(TSLA) ramps up competition.Nio stock reversed slightly Monday, while Xpeng and Li Auto also  fell.Year over year, Nio's April sales jumped 125% to 5,147 electric vehicles. That included 1,523 seven-seater ES8 SUVs, 3,163 five-seater ES6 SUVs, and 2,416 EC6 electric crossovers.Sales growth slowed from the 373% pace that Nio saw in March.But Nio's April EV sales defied the chip shortage that forced the emerging Tesla of China to temporarily suspend factory production for five days starting March 29.Year over year, Xpeng Motors saw April sales surge 285% to 5,147 electric vehicles. That included 2,995 P7 sedans and 2,152 G3 compact SUVs.However, growth slowed from March's 384% pace.Year over year, Li Auto's April sales increased 111% to 5,539 hybrid-electric SUVs. Sales growth slowed from March's 239% pace.Li Auto reached a milestone 500,000th delivery faster than any of its peers, the Chinese EV startup said in a statement.Month to month, Nio sales fell 2.1%. Nio last week indicated that Q2 deliveries would roughly flat vs. Q1 amid chip shortages. Xpeng sales rose 1% vs. March. Li Auto sales climbed 13% vs. the prior month.Nio Stock, Xpeng StockShares of Nio fell 0.75% to 39.54 on thestock market Monday after hitting 41.45 intraday. Nio stock has been meeting resistance at the 50-day line after bouncing off the 200-day line in mid-April. Xpeng stock fell 3% and hasn't traded above the 50-day line since February. Li Auto lost 1.5%.All three EV stocks remain in a severe bear market on a multitude of factors, including rising competition in China. Tesla, which dominates the Chinese market for luxury EVs, began selling a locally made Model Y SUV this year.Tesla stock slumped 3.5% amid a report that the key Berlin plant won't start production until 2022. Shares closed just above their declining 50-day line. TSLA stock rebounded above the 50-day line on Friday, after tumbling more than 8% in the three days after the EV maker's earnings.China EV Competition Heats UpAfter booming sales in 2020, Nio and Xpeng face tougher competition ahead. Tesla officially launched the new made-in-Shanghai Model Y crossover Jan. 1, a rival to Nio's EC6 and Xpeng's G7, and is ramping up sales. It already sold a locally made Model 3 sedan in China.Traditional auto giants are ramping up EV plans in China.Volkswagen(VWAGY) began deliveries of its made-in-China ID.4 crossover in late March.Ford(F) is taking preorders for Mach-E crossover, which is beginning local production.Last month, Tesla hiked prices of made-in-China Model Y SUVs. The price increase signaled that Tesla is \"comfortable\" with sales of its newest EV for the Chinese market, local reports said.As Tesla rises, Nio and its China EV stock peers all plan to introduce new, more attractively priced EVs. Last month,Xpeng showed off a smaller electric sedanthat it touts as the world's first mass-produced EV with lidar sensors.According to Wedbush analysts, \"China remains a greenfield EV market opportunity as we believe EV sales can potentially double in the region over the next few years.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":280,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":103053612,"gmtCreate":1619740273136,"gmtModify":1634210336239,"author":{"id":"3573681651019306","authorId":"3573681651019306","name":"Waffles_11","avatar":"https://static.tigerbbs.com/9d49a2f6994c90065ccb9ee9e61b94cd","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3573681651019306","idStr":"3573681651019306"},"themes":[],"htmlText":"Wow awesome&nbsp;","listText":"Wow awesome&nbsp;","text":"Wow awesome","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/103053612","repostId":"1161815718","repostType":4,"repost":{"id":"1161815718","kind":"news","pubTimestamp":1619685728,"share":"https://www.laohu8.com/m/news/1161815718?lang=&edition=full","pubTime":"2021-04-29 16:42","market":"us","language":"en","title":"25 Undervalued Stocks with Earnings Set to Beat Pre-Covid Levels in 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=1161815718","media":"MarketWatch","summary":"SinceBarron’slast screened for European stocks whose earnings prospects may not be fully priced in, ","content":"<p>Since<i>Barron’s</i>last screened for European stocks whose earnings prospects may not be fully priced in, the pan-EuropeanStoxx 600has climbed to record highs despite much of the continent battling a third wave of Covid-19.</p>\n<p>The index is now up more than 10% year-to-date but there are signs that more gains could be ahead, with Europe’s economic recoveryyet to really get going. Initiallyslow vaccination rolloutsin many European countries are starting to gather pace, and the U.K. notably reopened large parts of the economy earlier this month.</p>\n<p>Barclays’ European equity strategists devised a stock screen designed to find companies whose share price was lagging behind its earnings estimates. Their method screened for Stoxx 600 companies currently trading at least 5% below their levels at the end of 2019 and whose 2021 earnings per share, or EPS, estimates were above their pre-Covid 2019 EPS.</p>\n<p>“On this basis, consensus numbers suggest that the better earnings growth prospects of these stocks are not fully priced in, implying potentially attractive risk-reward ,” head of European equity strategy Emmanuel Cau said.</p>\n<p>Following a similar approach,<i>Barron’s</i>screened the Stoxx 600 for stocks trading more than 10% below their levels at the end of 2019 and filtered for companies that trade for no more than 20 times forward earnings estimates. The screen used FactSet consensus estimates instead of Barclays consensus estimates. The companies must also have a market capitalization above $10 billion.</p>\n<p>An earlier version of this screen at the end of Februarycontained 37 European companieswhose shares were more than 10% lower than their end-2019 levels.</p>\n<p>Since then, the index has jumped 6.8%, hitting record highs earlier this month. As a result the number of stocks in the screen dropped to 25 at the end of March and remains at 25 this time, with many departures down to rising share prices. However, there are still a number of stocks out there sitting below their 2019 levels but set to beat 2019 earnings this year—implying room for them to grow in the months ahead.</p>\n<p>Stocks Lagging EstimatesCompanies in the Stoxx 600 whose stock currently trade 10% or more below end-2019 levels but with 2021 earnings estimates above those of 2019, with a P/E ratio under 20.</p>\n<p><img src=\"https://static.tigerbbs.com/62565546aefb0d11006e4b97a5746aea\" tg-width=\"930\" tg-height=\"736\"><img src=\"https://static.tigerbbs.com/b281e399475bb5ee78464c4d57b43c14\" tg-width=\"932\" tg-height=\"706\"></p>\n<p>Four stocks have exited the screen: French telecoms companyOrange,insurance firmAxa,French defense groupThalesand Swiss-based Coke bottlerCoca-Cola HBC.&nbsp;Axa, Coca-Cola HBC and Thales have all seen their share prices rise in the past month, leading to their exit. Orange stock still remains 21% lower than it was at the end of 2019, but the telecoms giant’s 2021 EPS estimate has fallen in recent weeks, and is now expected to be flat compared to 2019.</p>\n<p>Four companies have entered the screen: French insurerCNP Assurances,Swedish telecoms companyTelia,Swiss bankCredit Suisseand Norwegian oil-and-gas producerAker BP.Shares in both CNP and Telia have slipped over the past month to more than 10% lower than their end-2019 levels. Credit Suisse features because analysts now forecast the bank’s 2021 EPS to beat that of 2019, while Aker BP’s market value has risen above $10 billion for its first inclusion in the screen.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>25 Undervalued Stocks with Earnings Set to Beat Pre-Covid Levels in 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n25 Undervalued Stocks with Earnings Set to Beat Pre-Covid Levels in 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-29 16:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/articles/25-undervalued-stocks-with-earnings-set-to-beat-pre-covid-levels-in-2021-51619641093?mod=mw_latestnews><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SinceBarron’slast screened for European stocks whose earnings prospects may not be fully priced in, the pan-EuropeanStoxx 600has climbed to record highs despite much of the continent battling a third ...</p>\n\n<a href=\"https://www.marketwatch.com/articles/25-undervalued-stocks-with-earnings-set-to-beat-pre-covid-levels-in-2021-51619641093?mod=mw_latestnews\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite"},"source_url":"https://www.marketwatch.com/articles/25-undervalued-stocks-with-earnings-set-to-beat-pre-covid-levels-in-2021-51619641093?mod=mw_latestnews","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161815718","content_text":"SinceBarron’slast screened for European stocks whose earnings prospects may not be fully priced in, the pan-EuropeanStoxx 600has climbed to record highs despite much of the continent battling a third wave of Covid-19.\nThe index is now up more than 10% year-to-date but there are signs that more gains could be ahead, with Europe’s economic recoveryyet to really get going. Initiallyslow vaccination rolloutsin many European countries are starting to gather pace, and the U.K. notably reopened large parts of the economy earlier this month.\nBarclays’ European equity strategists devised a stock screen designed to find companies whose share price was lagging behind its earnings estimates. Their method screened for Stoxx 600 companies currently trading at least 5% below their levels at the end of 2019 and whose 2021 earnings per share, or EPS, estimates were above their pre-Covid 2019 EPS.\n“On this basis, consensus numbers suggest that the better earnings growth prospects of these stocks are not fully priced in, implying potentially attractive risk-reward ,” head of European equity strategy Emmanuel Cau said.\nFollowing a similar approach,Barron’sscreened the Stoxx 600 for stocks trading more than 10% below their levels at the end of 2019 and filtered for companies that trade for no more than 20 times forward earnings estimates. The screen used FactSet consensus estimates instead of Barclays consensus estimates. The companies must also have a market capitalization above $10 billion.\nAn earlier version of this screen at the end of Februarycontained 37 European companieswhose shares were more than 10% lower than their end-2019 levels.\nSince then, the index has jumped 6.8%, hitting record highs earlier this month. As a result the number of stocks in the screen dropped to 25 at the end of March and remains at 25 this time, with many departures down to rising share prices. However, there are still a number of stocks out there sitting below their 2019 levels but set to beat 2019 earnings this year—implying room for them to grow in the months ahead.\nStocks Lagging EstimatesCompanies in the Stoxx 600 whose stock currently trade 10% or more below end-2019 levels but with 2021 earnings estimates above those of 2019, with a P/E ratio under 20.\n\nFour stocks have exited the screen: French telecoms companyOrange,insurance firmAxa,French defense groupThalesand Swiss-based Coke bottlerCoca-Cola HBC. Axa, Coca-Cola HBC and Thales have all seen their share prices rise in the past month, leading to their exit. Orange stock still remains 21% lower than it was at the end of 2019, but the telecoms giant’s 2021 EPS estimate has fallen in recent weeks, and is now expected to be flat compared to 2019.\nFour companies have entered the screen: French insurerCNP Assurances,Swedish telecoms companyTelia,Swiss bankCredit Suisseand Norwegian oil-and-gas producerAker BP.Shares in both CNP and Telia have slipped over the past month to more than 10% lower than their end-2019 levels. Credit Suisse features because analysts now forecast the bank’s 2021 EPS to beat that of 2019, while Aker BP’s market value has risen above $10 billion for its first inclusion in the screen.","news_type":1},"isVote":1,"tweetType":1,"viewCount":267,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}